Newsfeeds - Spark Newswire

2 minute read

Analyst Ratings

Evercore ISI Group Downgrades CRISPR Therapeutics: Here’s What You Need To Know

Today, 9:58 PM

Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics are trading up 3.81% over the last 24 hours, at $62.23 per share.

CRSP

20 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 23, 2022

By Benzinga Insights

Today, 9:58 PM

Upgrades

AAP

1 minute read

Oppenheimer Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $122

By Benzinga Newsdesk

Today, 9:58 PM

Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $150 to $122.

CRSP

1 minute read

Evercore ISI Group Downgrades CRISPR Therapeutics to In-Line, Lowers Price Target to $60

By Benzinga Newsdesk

Today, 9:58 PM

Evercore ISI Group analyst Liisa Bayko downgrades CRISPR Therapeutics (NASDAQ:CRSP) from Outperform to In-Line and lowers the price target from $66 to $60.

CRSP

1 minute read

Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $164

By Benzinga Newsdesk

Today, 9:58 PM

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $168 to $164.

CRSP

1 minute read

Stifel Maintains Hold on CRISPR Therapeutics, Lowers Price Target to $55

By Benzinga Newsdesk

Today, 9:58 PM

Stifel analyst Benjamin Burnett maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and lowers the price target from $57 to $55.

CRSP

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 17, 2022

By Benzinga Insights

Today, 9:58 PM

Upgrades

ACHC

1 minute read

CNBC’s Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock

By Priya Nigam

Today, 9:58 PM

On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr.

1 minute read

Analysts Consider CRISPR Therapeutics’ Blood Disorder Trial Data Encouraging, Impressive

By Vandana Singh

Today, 9:58 PM

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

BLUE

4 minute read

70 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 9:58 PM

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.

ABVC